Isomorphic Labs raises $5 billion, its second billion-dollar round in six months
Greenoaks and Sequoia co-led the round, with Andreessen Horowitz joining as a new backer, while the Alphabet unit still has no approved drug.
What happened
Isomorphic Labs is Alphabet's AI drug discovery company. It has raised $5 billion from investors. It raised $2.1 billion in May 2026, so this is its second huge round in six months.
Why it matters to you
The money funds AI tools meant to design medicines faster. If they work, new drugs could reach patients sooner, but none has been approved yet.
The takeaway
Investors are betting big on AI-designed drugs, but the company has no approved drug so far.
What it means for you
IsoDDE is the in-house platform to track, with the company claiming it improves on AlphaFold 3 for binding and docking site prediction.
Pharma partners Novartis, Eli Lilly and Johnson & Johnson already work with Isomorphic, so AI-led drug design is entering established partnerships.
Two rounds totaling $7.1 billion in six months show heavy capital flowing in, yet the company has no approved drug to show for it.